CDC-AGO, a Targeted Mosquito Trap
Laboratory: Centers for Disease Control and Prevention
Technology: Autocidal Gravid Ovitrap Mosquito Trap for Control and Surveillance of Mosquitoes
Opportunity: Available for licensing
Details: Mosquitoes are responsible for the transmission of a number of important zoonotic diseases, including dengue fever, malaria, zika, Rift Valley fever, and West Nile virus. The CDC-AGO (Autocidal Gravid Ovitrap) mosquito trap is a device that targets older female mosquitoes looking for a suitable place to lay eggs. This device is 45 centimeters tall with a 10-liter capacity to hold an attractant, such as water and decaying vegetation. The mosquitoes are captured by a nontoxic adhesive, and eggs are collected on a hydrogel. The use of the hydrogel instead of a liquid prevents the larvae from hatched mosquito eggs from completing development.
Benefits: Over time, insecticide compounds degrade and mosquito populations can become insecticide-resistant, so many chemical ovitraps currently on the market are short-lived. Unlike other mosquito control methods, the CDC-AGO addresses this need with its use of nontoxic adhesive and hydrogel polymer instead of insecticide.
Potential Applications:
- Device for mosquito control
- May be useful in regions of the world affected by vector-borne zoonotic diseases
Contact: For more information about this award-winning technology, contact TTO@cdc.gov or Lisa Marianni, RN, MBA at lmarianni@cdc.gov.
View the original listing for this technology from the National Institutes of Health’s Office of Technology Transfer, which administers the CDC’s technology transfer program.